What is the current evidence for GLP1 receptor agonists as disease modifying agents in multiple sclerosis, beyond metabolic and weight effects?

I am conducting a PROSPERO registered systematic review and meta analysis on GLP-1 receptor agonists in multiple sclerosis (CRD420261385854). I am seeking expert perspectives on whether current preclinical and clinical evidence supports a disease modifying mechanism or whether observed benefits are secondary to metabolic and weight improvements.